<div class="wrapper wrapper-5">
  <h1 class="pt-5">LA RECHERCHE CLINIQUE</h1>
</div>
<div class="container">
  <div class="row mx-auto text-justify py-3">
    The GFAOP demonstrated that, even in Africa, clinical research could be done prospectively and multicentre. 5 tumor committees, one for each type of cancer, manage clinical studies and care protocol adaptations.
    Clinical researchers collect data that is analyzed and centralized in Gustave Roussy.
  </div>
  <div class="row mx-auto text-justify">
    There are 5 types of cancer that are treated under GFAOP.
    They account for about 70% of local cancers with a high chance of remission when treated early enough :
  </div>
  <div class="row mx-auto text-justify">
    <ul>
      <li>Nephroblastoma (kidney cancer)</li>
      <li>Retinoblastoma (eye cancer)</li>
      <li>Acute lymphoblastic leukemia</li>
      <li>Hodgkin's disease</li>
      <li>Burkitt's lymphoma</li>
    </ul>
  </div>
</div>
<hr class="separator">
<div class="container">
  <h3 class="text-center py-3">Tumor Committees</h3>
  <div class="row text-center">
    <div class="col-12 col-md-3 cream rounded m-2 ml-md-auto">
      <h4 class="py-1">Burkitt Committee</h5>
      <h6>Coordinator : Maria El Kababri (Rabat, Marocco)</h6>
      <h6>Data manager : Marie-Anne Raquin (IGR, France)</h6>
      <h6>Secretary : Angèle Pondy (Yaoundé, Cameroon)</h6>
      <h6>Expert: Catherine Patte (IGR, France)</h6>
    </div>
    <div class="col-12 col-md-3 cream rounded m-2">
      <h4 class="py-1">Nephroblastoma Committee</h5>
      <h6>Coordinator : Claude Moreira (Dakar, Senegal)</h6>
      <h6>Data manager : Brenda Mallon (IGR, France)</h6>
      <h6>Secretary : Jean Jacques Atteby (Treichville, Ivory Coast)</h6>
      <h6>Expert: Catherine Patte (IGR, France)</h6>
    </div>
    <div class="col-12 col-md-3 cream rounded m-2 mr-md-auto">
      <h4 class="py-1">Retinoblastoma Committee</h5>
      <h6>Coordinator : Fousseyni Traoré (Bamako, Mali)</h6>
      <h6>Expert : Pierre Bey (Curie, France)</h6>
    </div>
  </div>
  <div class="row text-center">
    <div class="col-12 col-md-3 cream rounded m-2 ml-md-auto">
      <h4 class="py-1">Hodgkin lymphoma committee</h5>
      <h6>Coordinator : Christine Edan (Rennes, France)</h6>
      <h6>Data manager : Souad Nafa (IGR, France)</h6>
      <h6>Expert : Odile Oberlin</h6>
    </div>
    <div class="col-12 col-md-3 cream rounded m-2 mr-md-auto">
      <h4 class="py-1">Leukemia Acute Lymphoblastic Committee</h5>
      <h6>Coordinator : Marie Dominique Tabone</h6>
      <h6>Data manager : Clinical Research Unit (Trousseau, France)</h6>
      <h6>Expert : Guy Leverger (Armand Trousseau hospital)</h6>
    </div>
  </div>
</div>

<hr class="separator">

<div class="container">
  <h4 class="text-center py-2">The clinical studies conducted since the creation of the GFAOP show encouraging results.</h4>
  <div class="row text-justify">
    <div class="col-12 col-md-6">
      <p>Thus, for Burkitt and nephroblastoma, two successive studies carried out between 2000 and 2009 indicate the following survival rates :</p>
      <p>- 60% for Burkitt's Lymphomas (study directed by Professor Catherine Patte from the IGR and Dr Maria El Kababri from Rabat)</p>
      <p>- 70% for nephroblastomas (study directed by Professor Catherine Patte from the IGR and Professor Claude Moreira from Dakar)</p>
      <p>- For Hodgkin's disease, overall survival was 82% in our 2006-2012 study over 89 cases.</p>
    </div>
    <div class="col-12 col-md-6">
      <p>- For acute lymphoblastic leukemias, the latest study conducted by the GFAOP, with the expertise of Professor Guy Leverger from Armand Trousseau Hospital in Paris, shows a disease-free survival rate in sub-Saharan Africa of 60% at the end of the treatment, whose total duration is two years.</p>
      <p>- For retinoblastomas, 112 cases have observed in Bamako since the launch of the program in October 2011 with more than 90% healing.</p>
    </div>
  </div>
</div>